{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:27:51Z","timestamp":1789518471087,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.cllc.2019.02.009","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T02:43:57Z","timestamp":1551149037000},"page":"e274-e283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non\u2013small-cell Lung Carcinoma and Brain Metastases"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6380-3527","authenticated-orcid":false,"given":"Yu-Feng","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chor-Kuan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Song","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2019.02.009_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.21037\/tlcr.2016.10.16","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future","volume":"5","author":"Proto","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2019.02.009_bib2","doi-asserted-by":"crossref","first-page":"e000262","DOI":"10.1136\/esmoopen-2017-000262","article-title":"Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion","volume":"3","author":"Preusser","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.cllc.2019.02.009_bib3","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.jtho.2016.06.002","article-title":"Brain metastases from NSCLC: radiation therapy in the era of targeted therapies","volume":"11","author":"Khalifa","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.02.009_bib4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10147-014-0760-9","article-title":"Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations","volume":"20","author":"Iuchi","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.cllc.2019.02.009_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11060-017-2590-x","article-title":"High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases","volume":"135","author":"Ge","year":"2017","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.cllc.2019.02.009_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.lungcan.2016.04.004","article-title":"EGFR mutation status on brain metastases from non-small cell lung cancer","volume":"96","author":"Hsu","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2019.02.009_bib7","first-page":"1136","article-title":"Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden","volume":"20","author":"Fernandes","year":"2017","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.cllc.2019.02.009_bib8","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/annonc\/mdh276","article-title":"Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial","volume":"15","author":"Ceresoli","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2019.02.009_bib9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.lungcan.2013.08.016","article-title":"Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma","volume":"82","author":"Iuchi","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2019.02.009_bib10","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1183\/09031936.00195609","article-title":"Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation","volume":"37","author":"Porta","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cllc.2019.02.009_bib11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ijrobp.2014.02.022","article-title":"Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma","volume":"89","author":"Gerber","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2019.02.009_bib12","doi-asserted-by":"crossref","first-page":"57356","DOI":"10.18632\/oncotarget.19054","article-title":"Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2019.02.009_bib13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","article-title":"First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases","volume":"11","author":"Schuler","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.02.009_bib14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JTO.0000000000000380","article-title":"Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease","volume":"10","author":"Hoffknecht","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.02.009_bib15","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdw322","article-title":"Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials","volume":"27","author":"Yang","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2019.02.009_bib17","doi-asserted-by":"crossref","first-page":"90430","DOI":"10.18632\/oncotarget.19563","article-title":"Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma","volume":"8","author":"Liang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2019.02.009_bib18","doi-asserted-by":"crossref","first-page":"97602","DOI":"10.18632\/oncotarget.18746","article-title":"The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2019.02.009_bib19","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1186\/s12885-018-5110-2","article-title":"Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases","volume":"18","author":"Tan","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2019.02.009_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2018.07.128","article-title":"Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: how low can we go?","volume":"103","author":"Lim","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2019.02.009_bib21","doi-asserted-by":"crossref","first-page":"23749","DOI":"10.18632\/oncotarget.25255","article-title":"Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study","volume":"9","author":"Liang","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2019.02.009_bib22","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2019.02.009_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2019.02.009_bib24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/14737140.2018.1409623","article-title":"Response to afatinib in treatment-naive patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases","volume":"18","author":"Li","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.cllc.2019.02.009_bib25","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2016.05.013","article-title":"EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases","volume":"11","author":"Jiang","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.02.009_bib26","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2147\/OTT.S156570","article-title":"Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer","volume":"11","author":"Wang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.cllc.2019.02.009_bib27","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2016.69.7144","article-title":"Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis","volume":"35","author":"Magnuson","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.02.009_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2018.05.014","article-title":"Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: a meta-analysis","volume":"122","author":"Wang","year":"2018","journal-title":"Lung Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419300592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419300592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:09:42Z","timestamp":1761505782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730419300592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1525730419300592"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2019.02.009","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non\u2013small-cell Lung Carcinoma and Brain Metastases","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2019.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}